Abstract
Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1278-1284 |
| Number of pages | 7 |
| Journal | Head and Neck |
| Volume | 33 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2011 |
Fingerprint
Keywords
- TRAIL
- TRAIL receptor
- clinical and pathologic staging
- head and neck cancer
- molecular diagnostics
Cite this
Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer. / Yoldas, Burcak; Ozer, Cem; Ozen, Ozlem; Canpolat, Tuba; Dogan, Isilay; Griffith, Thomas S.; Sanlioglu, Salih; Ozluoglu, Levent N.
In: Head and Neck, Vol. 33, No. 9, 01.09.2011, p. 1278-1284.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical significance of TRAIL and TRAIL receptors in patients with head and neck cancer
AU - Yoldas, Burcak
AU - Ozer, Cem
AU - Ozen, Ozlem
AU - Canpolat, Tuba
AU - Dogan, Isilay
AU - Griffith, Thomas S.
AU - Sanlioglu, Salih
AU - Ozluoglu, Levent N.
PY - 2011/9/1
Y1 - 2011/9/1
N2 - Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010
AB - Background. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a death ligand currently under clinical trials for cancer. The molecular profile of TRAIL and TRAIL receptors has not yet been mapped for patients with laryngeal squamous cell carcinoma (SCC) or patients with oral cavity squamous cell carcinoma (OCSCC). Methods. Paraffin-embedded tissues from 60 patients with laryngeal SCC and 14 patients with OCSCC were retrospectively analyzed using immunohistochemistry. Results. An increase in decoy-R1 (DcR1) but a decrease in decoy-R2 (DcR2) expression were observed in patients with laryngeal SCC and in patients with OCSCC compared with control individuals with benign lesions. Clinical and pathologic grading revealed distinctive TRAIL and TRAIL receptor profiles in patients with squamous cell carcinoma of the head and neck (SCCHN). Conclusions. TRAIL and a TRAIL receptor expression profile might be useful to follow-up disease progression by virtue of its connection with clinical staging and pathologic grading in patients with laryngeal SCC. © 2010 Wiley Periodicals, Inc. Head Neck, 2010
KW - TRAIL
KW - TRAIL receptor
KW - clinical and pathologic staging
KW - head and neck cancer
KW - molecular diagnostics
UR - http://www.scopus.com/inward/record.url?scp=80051743553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051743553&partnerID=8YFLogxK
U2 - 10.1002/hed.21598
DO - 10.1002/hed.21598
M3 - Article
C2 - 21837697
AN - SCOPUS:80051743553
VL - 33
SP - 1278
EP - 1284
JO - Head and Neck Surgery
JF - Head and Neck Surgery
SN - 1043-3074
IS - 9
ER -